What this study is
The purpose of this research study is to evaluate the effect of low-dose aspirin on recovery from severe preeclampsia (a high blood pressure disorder of pregnancy) among women who have given birth. We hypothesize that taking aspirin for the first week after giving birth will enhance recovery from preeclampsia by decreasing the levels of a protein called soluble fms-like tyrosine kinase (sFlt-1), which is thought to be a main contributor to the development of preeclampsia, and speeding up return to a normal blood pressure.
What's being tested
- Aspirin 81Mg Ec Tab
Intervention · DRUG
Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.
Study details
- Official title
- Acetylsalicylic Acid for Postpartum Preeclampsia: A Pilot Randomized Trial
- Sponsor
- MemorialCare Health System
- Conditions
- Preeclampsia Postpartum
- Enrolling
- 86 people
- Starts
- 2023-07-26
- Est. completion
- 2026-12
- Design
- Single-blind, randomized, parallel groups, Phase 2
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex FEMALEHealthy volunteers Not acceptedYou may qualify if
- Preeclampsia with severe features diagnosed during delivery admission, as defined by ACOG criteria.
- Pre- and postnatal care provided by the Long Beach Memorial Ob/Gyn resident or Maternal-Fetal Medicine clinic.
You can't join if
- Patient age <18 years old
- Non-English or Non-Spanish speaking
- Chronic hypertension diagnosed before 20 weeks' gestation
- Known allergy, prior adverse reaction, or any medical condition in which aspirin is contraindicated (nasal polyps, gastric or duodenal ulcers, history of gastrointestinal bleeding, severe hepatic dysfunction)
- Aspirin prescribed postpartum for any other medical condition
- Bleeding disorder
- Breastfeeding an infant with thrombocytopenia
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openMiller Children's and Women's Hospital, Long Beach/MemorialCare Long Beach
Long Beach, California, United States
- Megan Oakes, MD · Contact562-997-8510moakes2@memorialcare.org
Recruiting
Study team
Sponsor
MemorialCare Health System
Study ID 371-23
Principal investigator
Megan C Oakes, MD MSCI
Miller Children's and Women's Hospital, Long Beach/ MemorialCare Medical Center
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.